
Have You Been Diagnosed with Adrenocortical Carcinoma?

If you or your loved one has adrenocortical carcinoma, then a clinical research study may be of interest to you.

ABOUT THE STUDY

[Corcept Therapeutics](#) is now looking for volunteers to participate in a clinical study of the investigational study drug, relacorilant, in combination with the immunotherapy drug, Keytruda® (pembrolizumab)*.

Purpose

The purpose of this clinical study is to test the safety (side effects) and efficacy (benefits) of relacorilant when given together with Keytruda, for the treatment of advanced adrenocortical cancer (ACC) which produces too much stress hormone (cortisol).

Who May Qualify?

Adults diagnosed with advanced adrenocortical carcinoma (ACC) which produces too much stress hormone (cortisol). Additional eligibility criteria can be found at ClinicalTrials.gov/NCT04373265.

Where Are The Study Sites?

Institution Name	City, State
The University of Texas, M.D. Anderson Cancer Center	Houston, Texas
University of Michigan, Health System	Ann Arbor, Michigan
Stanford Cancer Center	Palo Alto, California
H. Lee Moffitt Cancer Center	Tampa, Florida
Mayo Clinic	Rochester, Minnesota

[If there is not a research site near you but you are willing to travel, compensation for reasonable travel expenses may be available.](#)

Contact:

If you or someone you know may be interested in participating in this study, please contact Corcept Therapeutics:

Call: 650-327-3270

Email: study551@corcept.com

To learn more about this study, visit: [National Cancer Institute](https://www.nationalcancerinstitute.gov) or ClinicalTrials.gov/NCT04373265

Will All Study Participants Receive Investigational Study Drug?

All study participants will receive the investigational study drug, relacorilant, as well as Keytruda for as long as deemed appropriate and beneficial by their physician.

Will I Have To Pay To Participate?

There will be no cost to you for any study-related medical exams or laboratory tests. Those who qualify will receive the investigational study drug, relacorilant, as well as the immunotherapy drug, Keytruda at no cost. If there is not a research site near you but you are willing to travel, compensation for reasonable travel expenses may be available.

*KEYTRUDA is a trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.